Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.

Autor: Gutierrez-Sainz L; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain. laura.gutierrezsainz@gmail.com., Martinez-Fdez S; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Pedregosa-Barbas J; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Peña J; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Alameda M; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Viñal D; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Villamayor J; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Martinez-Recio S; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Perez-Wert P; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Pertejo-Fernandez A; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain., Gallego A; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain., Martinez-Marin V; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Translational Oncology Group, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain., Zamora P; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Translational Oncology Group, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.; Cátedra UAM-AMGEN, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain., Espinosa E; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Translational Oncology Group, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.; Cátedra UAM-AMGEN, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.; Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Mendiola M; Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Molecular Pathology and Therapeutic Targets Group, IdiPAZ, Madrid, Spain., Feliu J; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.; Translational Oncology Group, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.; Cátedra UAM-AMGEN, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.; Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Redondo A; Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain. andres.redondos@uam.es.; Translational Oncology Group, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. andres.redondos@uam.es.; Cátedra UAM-AMGEN, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. andres.redondos@uam.es.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Dec; Vol. 25 (12), pp. 3519-3526. Date of Electronic Publication: 2023 Jun 17.

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.

Autor: Martin-Broto J; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain. jmartin@atbsarc.org.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Av. de los Reyes Católicos, 2, 28040, Madrid, Spain. jmartin@atbsarc.org.; General de Villalba University Hospital, 28400, Madrid, Spain. jmartin@atbsarc.org., Valverde C; Medical Oncology department, Vall d'Hebron University Hospital, 08035, Barcelona, Spain., Hindi N; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Av. de los Reyes Católicos, 2, 28040, Madrid, Spain.; General de Villalba University Hospital, 28400, Madrid, Spain., Vincenzi B; Medical Oncology, University Campus Bio-Medico and Fondazione Policlinico Universitario Campus Bio-Medico, 00128, Rome, Italy., Martinez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, 50009, Zaragoza, Spain., Grignani G; Medical Oncology Unit, Città della Salute e della Scienza Hospital, 10126, Turin, Italy., Italiano A; Medical Oncology department, Institute Bergonié, 33076, Bordeaux, France., Lavernia J; Medical Oncology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Vallejo A; Pathology department, Hospital Regional Universitario de Malaga, 29010, Malaga, Spain., Tos PD; Department of Medicine, School of Medicine, University of Padua, 35122, Padua, Italy., Le Loarer F; Pathology department, Institute Bergonié, 33076, Bordeaux, France., Gonzalez-Campora R; Pathology department, Hospital Quironsalud, 14004, Cordoba, Cordoba, Spain., Ramos R; Pathology department, University Hospital Son Espases, 07120, Mallorca, Spain., Hernández-Jover D; Radiology department, Sant Pau University Hospital, 08025, Barcelona, Spain., Gutierrez A; Hematology department, University Hospital Son Espases, 07120, Mallorca, Spain., Serrano C; Medical Oncology department, Vall d'Hebron University Hospital, 08035, Barcelona, Spain., Monteagudo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Letón R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Robledo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Moura DS; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain., Martin-Ruiz M; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain., López-Guerrero JA; Molecular Biology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Cruz J; Pathology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Fernandez-Serra A; Molecular Biology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Blay JY; Medicine Department, Centre Léon Bérard, 69008, Lyon, France., Fumagalli E; Medicine Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133, Milan, Italy., Martinez-Marin V; Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, P. Castellana, 261, 28046, Madrid, Spain.

Publikováno v: Molecular cancer [Mol Cancer] 2023 Aug 09; Vol. 22 (1), pp. 127. Date of Electronic Publication: 2023 Aug 09.

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

Autor: Martin, A, Diaz, E, Escobar, I, Montero, R, Martinez-Marin, V, Olmos, V, Segura, P, Verduguez, T, Fernandez, M

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

In 2011, the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of venous thromboembolism (VTE) and cancer. This guideline was updated in 2014, and since then, multiple studies and clinical trials have changed the landsca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2ab28eed94d12fca78cdc9dd51d87891
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9137

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.